Autolus Therapeutics - jetzt einsteigen?
Seite 1 von 3 Neuester Beitrag: 21.11.24 16:13 | ||||
| Eröffnet am: | 16.02.20 18:35 | von: moneywork4. | Anzahl Beiträge: | 54 |
| Neuester Beitrag: | 21.11.24 16:13 | von: Vermeer | Leser gesamt: | 17.562 |
| Forum: | Hot-Stocks | Leser heute: | 33 | |
| Bewertet mit: |  | |||
| Seite: < | 2 | 3 > | ||||
https://www.finanzen.net/aktien/...us_therapeutics-aktie@stBoerse_NAS
https://www.analystratings.com/articles/...ating-from-h-c-wainwright/
https://www.autolus.com/
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Autolus Therapeutics pl |
https://autolus.gcs-web.com/news-releases/...t-quarter-2021-financial
Optionen
| Boardmail an "Vassago" |
Wertpapier: Autolus Therapeutics pl |
- AUTL gab in einer frühen Studie bekannt, dass seine experimentelle CD19-Zelltherapie AUTO1 bei Patienten mit rezidiviertem / refraktärem indolentem Non-Hodgkin-Lymphom eine100% ige Remission erreicht hatte
- die Ergebnisse von AUTO1 werden in einer Präsentation auf dem virtuellen Kongress der European Hematology Association (EHA) vom 9. bis 17. Juni enthalten sein
- von 10 Patienten seien 9 auswertbar gewesen, alle 9 erreichten vollständige Remissionsraten
- bei keinem der Patienten wurde ein hochgradiges Zytokinfreisetzungssyndrom (CRS) oder Neurotoxizität beobachtet
- bei vier Patienten trat jedoch ein CRS Grad 1 (mild) und bei einem Patienten ein CRS Grad 2 (moderat) auf
Die Aktie von AUTL stieg daraufhin um ca. 35% von 5 auf 7$, aktuell bei 6$.
https://www.fool.com/investing/2021/05/12/...stock-skyrocketed-today/
"It is still early days for the trial—the median duration of response is 3.1 months—and the sample size is small."
https://www.fiercebiotech.com/biotech/...e-3-crs-small-lymphoma-trial
AUTO4 in Peripheral T Cell Lymphoma (PTCL), next data update in the second half of 2021
Optionen
| Boardmail an "Vassago" |
Wertpapier: Autolus Therapeutics pl |
oder steckt mehr dahinter?
https://www.nasdaq.com/market-activity/stocks/autl/short-interest
nach dem Kongress wissen wir mehr..
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Autolus Therapeutics pl |
Kollaboration mit BMS
"Autolus erhält eine Vorauszahlung mit dem Potenzial für kurzfristige Optionsausübungsgebühren und Entwicklungsmeilensteinzahlungen sowie Lizenzgebühren"
https://autolus.gcs-web.com/news-releases/...laboration-bristol-myers
Optionen
| Boardmail an "Vassago" |
Wertpapier: Autolus Therapeutics pl |
LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the handover of the first of three clean rooms forming the basis of its new commercial manufacturing facility in Stevenage, UK. This anchor facility has been named ‘The Nucleus’, chosen from Autolus staff suggestions.
The Nucleus facility is part of a larger plan to create a life sciences district in the heart of Stevenage town center by developers, Reef Group. The site has been created via a joint venture between UBS Asset Management and Reef Group to invest up to £120 million to redevelop Stevenage town center, working with key stakeholders including Hertfordshire Local Enterprise Partnership and Stevenage Borough Council. The new quarter will aim to house the largest cluster of Cell and Gene Therapy companies outside the United States. The build for The Nucleus has been completed for Autolus by design and construction specialists, Merit.
“The Phase 1 completion of The Nucleus facility is a major milestone for Autolus, as well as for the town of Stevenage,”
said Dave Brochu, Chief Technical Officer of Autolus.
“The entire project team, including Autolus, Merit, and Reef Group have successfully kept this project on track despite challenging timelines, the COVID pandemic, and supply chain constraints. These efforts have enabled us to transition seamlessly into the next phase of growth for Autolus.”
“Reef Group is incredibly proud to have led a truly innovative collaboration between Autolus, Merit and our funding partners, UBS, where many industry ‘firsts’ were achieved,”
said Piers Slater, Chief Executive Officer of Reef Group.
“The ‘can do’ attitude from all the partners, in no small part inspired and driven by the Autolus Executive Team and facilitated by the unique Reef Merit approach to volumetric build, was instrumental in the delivery of a project that we believe sets a new benchmark for the Good Manufacturing Practice (GMP) industry.”
“To deliver this important milestone after only 17.5 months from start of design and planning and with only 12.5 months on-site is a fantastic achievement for the whole team. Merit is proud to have played a part in it,”
said Tony Wells, Chief Executive Officer of Merit.
“The Autolus Executive Management team provided clear directions and set challenging targets for quality and delivery schedule, which have driven innovation throughout the project. It has been a fun, collaborative and exciting opportunity for everyone involved at Merit.”
150 Mio. $ Offering
- 75 Mio. ADS zu je 2$
https://autolus.gcs-web.com/news-releases/...ricing-public-offering-2
Zahlen für Q3/22
- Umsatz 2 Mio. $
- Verlust 43 Mio. $
- Cash 163 Mio. $
- MK 273 Mio. $
"Autolus estimates that its current cash on hand and anticipated milestone payments in the relevant period from Blackstone extends the Company’s runway into 2024."
https://autolus.gcs-web.com/news-releases/...d-quarter-2022-financial
Optionen
| Boardmail an "Vassago" |
Wertpapier: Autolus Therapeutics pl |
LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into a non-exclusive license agreement with Cabaletta Bio, Inc (Nasdaq: CABA). The agreement allows Cabaletta to incorporate Autolus’ proprietary RQR8 safety switch 1 into a cell therapy program for the treatment of autoimmune disease, with an option for Cabaletta to incorporate the safety switch in up to four additional cell therapy programs.
“We are delighted to partner with Cabaletta and to expand the use of our safety switches in autoimmune disease,” said Dr. Martin Pule, Chief Scientific Officer of Autolus . “Safety switches are critical to the future of our field of advanced cell therapies. They allow us to develop approaches that are designed to significantly improve patient outcomes, whilst at the same time potentially reducing the risk of adverse side effects from the treatment.”
Under the terms of the agreement, Autolus will receive an upfront payment for non-exclusive access to the RQR8 safety switch for use in Cabaletta’s CD19-CAR T cell therapy program for the treatment of autoimmune disease, with the potential for near term option exercise fees and development and regulatory milestone payments. In addition, Autolus is entitled to receive royalties on net sales of all Cabaletta cell therapy products that incorporate the RQR8 safety switch.
This agreement demonstrates how Autolus is able to generate value from its technologies and pipeline and follows similar deals with Bristol Myers Squibb and Moderna .
LONDON, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces two changes to the company’s Board of Directors.
The company’s non-executive Chairman, John H Johnson, who has held the role since September 2021, will not stand for re-election at Autolus’ upcoming annual shareholder meeting. During his tenure as Chairman of Autolus he was appointed as Chief Executive Officer (CEO) of Reaction Biology and will focus his time on his operational role.
Additionally, Dr Jay T Backstrom, who has served on Autolus’ Board of Directors since August 2020, will step down from Autolus’ Board of Directors at the end of February 2023. Dr Backstrom was recently appointed as CEO of Scholar Rock and will focus his time on his operational role in line with good governance recommendations for public company CEOs.
“The Autolus Board and management team would like to thank John and Jay for their contributions and support during an important period in the company’s transition to a late-stage biopharmaceutical company,” said Dr. Christian Itin, Chief Executive Officer of Autolus . “During their tenure, Autolus’ lead product candidate obe-cel met the primary end point in the pivotal FELIX trial and the company has started preparing for the regulatory approval process, as well as initiating preparations for commercialization.”
Searches to replace both Board members have been initiated.